Oxytocin and Reward Processing in Women
The Role of Oxytocin in Reward Processing Across the Menstrual Cycle and With Oral Contraceptive Use
International Research Training Group 2804
100 participants
Feb 16, 2024
INTERVENTIONAL
Conditions
Summary
Oxytocin is a hypothalamic neuropeptide that is best known for its peripheral physiological effects in the female organism i.e., uterine contractions during birth. The neuropeptide furthermore affects reward processing and metabolic functions such as eating behavior and body weight. Oxytocin receptors are present in brain regions associated with the processing of rewards, e.g., ventral tegmental area (VTA), nucleus accumbens (NAcc) and nucleus stria terminalis. Previous studies indicate that oxytocin interacts with sex hormones such as estradiol in a sex-specific manner. Despite known sex differences in oxytocin function, most studies i.e., on the metabolic effects of oxytocin in humans have so far focused on young, healthy men. Intranasal oxytocin administration has emerged as a method to experimentally investigate central nervous effects of oxytocin in the absence of relevant side effects. In the proposed study the investigators aim to systematically investigate the acute effect of intranasal oxytocin on reward processing in relation to circulating and synthetic sex hormones in healthy, naturally cycling women and in women taking hormonal oral contraceptive pills. The investigators will administer 24 international units (IU) of intranasal oxytocin vs. placebo and investigate neural correlates in a 3T MRI scanner including functional imaging during a reward processing task, changes in brain anatomy and connectivity. Additionally, metabolic functions, eating behavior and changes in mood and wellbeing will be assessed and blood will be drawn to assess parameters of hormonal and metabolic status.
Eligibility
Inclusion Criteria6
- Body-mass index (BMI): 18-28 kg/m2
- Sex: female (since birth)
- Normal or corrected vision
- Natural menstrual cycle (NC) or intake of hormonal oral contraceptives (OC)
- NC: No hormonal contraception for at least 6 months; regular menstrual cycle (between 25 and 31 days) prior to participation
- OC: No hormonal contraception for at least 4 months, regular intake of OC pill
Exclusion Criteria20
- No German language fluency (due to German language test content)
- Smoking
- Medication taken within the last 6 weeks (except for OCs in the respective group)
- Current neurological or psychiatric disease (anamnestic survey)
- Current medical problems such as hormonal, metabolic, or chronic diseases (e.g., severe hypertension, diabetes, dysfunctions of the thyroid, or congestive heart failure)
- Pregnancy, delivery and lactation (current and within the last year; anamnestic survey, current pregnancy test)
- Premenstrual dysphoric disorder (PMDD), endometriosis or polycystic ovary syndrome (PCOS)
- Shift work
- NC: Any kind of hormonal treatment or contraception
- OC: Any kind of hormonal treatment or contraception (except OCs)
- Contraindication for MRI:
- Non-removable metal objects on or in the body
- Tattoos (if MRI-incompatible according to expert guidelines)
- Pathological hearing or increased sensitivity to loud noise
- Claustrophobia
- Operation less than three months ago
- Neurological disease or injury
- Moderate or severe head injury
- Intake of antidepressants or neuroleptics
- Restricted vision
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
24 international units (IU) of Syntocinon, nasal spray solution; 1 ml nasal spray contains 40 I.U. oxytocin (equivalent to 67 mcg). One spray hub (0.1 ml) contains 4 I.U. oxytocin (equivalent to 6.7 mcg).
Nasal spray solution; Placebo will be administered as the placebo controlled condition.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06222749